KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elevance Health (ELV) Exchange Rate Effect (2016 - 2025)

Elevance Health (ELV) has disclosed Exchange Rate Effect for 17 consecutive years, with -$6.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Exchange Rate Effect rose 25.0% to -$6.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$5.0 million, a 16.67% increase, with the full-year FY2025 number at -$5.0 million, up 16.67% from a year prior.
  • Exchange Rate Effect was -$6.0 million for Q4 2025 at Elevance Health, down from -$1.0 million in the prior quarter.
  • In the past five years, Exchange Rate Effect ranged from a high of $7.0 million in Q3 2024 to a low of -$8.0 million in Q4 2024.
  • A 5-year average of -$1.9 million and a median of -$1.0 million in 2021 define the central range for Exchange Rate Effect.
  • Peak YoY movement for Exchange Rate Effect: soared 300.0% in 2022, then tumbled 900.0% in 2024.
  • Elevance Health's Exchange Rate Effect stood at -$1.0 million in 2021, then skyrocketed by 300.0% to $2.0 million in 2022, then plummeted by 50.0% to $1.0 million in 2023, then crashed by 900.0% to -$8.0 million in 2024, then rose by 25.0% to -$6.0 million in 2025.
  • Per Business Quant, the three most recent readings for ELV's Exchange Rate Effect are -$6.0 million (Q4 2025), -$1.0 million (Q3 2025), and $1.0 million (Q2 2025).